KEY FEATURES
Full Name | Endoplasmic Reticulum Resident Protein 57 |
---|---|
Synonym | P58; ERp61; PDIA3; ERp60; GRP57; PI-PLC; GRP58; Glucose Regulated Protein,58kDa; Protein Disulfide Isomerase-Associated 3; Endoplasmic reticulum resident protein 57 |
Assay Type | Sandwich |
Reactivity | Human |
Range | 0.15-10ng/mL |
Sensitivity | 0.06ng/mL |
Sample Type | Serum,plasma and other biological fluids |
Sample Volume | 100μL |
Detection Wavelength | OD450 |
Transportation Temperature | 2-8°C |
Specificity | The kit detected Human ERp57 in the samples and no significant cross-species reactions were found |
Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human ERp57. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human ERp57 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human ERp57, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human ERp57. You can calculate the concentration of Human ERp57 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
Components | Specifications | Storage and Notes |
---|---|---|
Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human ERp57 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
Intra-assay Precision | Inter-assay Precision | |||||
---|---|---|---|---|---|---|
Sample | 1 | 2 | 3 | 1 | 2 | 3 |
n | 20 | 20 | 20 | 20 | 20 | 20 |
Mean (ng/mL) | 0.5 | 1.16 | 4.18 | 0.46 | 1.07 | 4.53 |
Standard deviation | 0.03 | 0.05 | 0.16 | 0.03 | 0.06 | 0.22 |
CV(%) | 6.81 | 4.18 | 3.9 | 5.59 | 5.26 | 4.91 |
RECOVERY
The recovery of Human ERp57 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
Sample Type | Range (%) | Average Recovery (%) |
---|---|---|
Serum(n=8) | 91-104 | 97 |
EDTA plasma (n=8) | 88-99 | 93 |
Cell culture media (n=8) | 93-107 | 101 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human ERp57 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with PDIA3 ELISA Kits
STAT3 ELISA Kit | publications with PDIA3 and STAT3 |
HLA-B ELISA Kit | publications with PDIA3 and HLA-B |
HLA-A ELISA Kit | publications with PDIA3 and HLA-A |
CALR ELISA Kit | publications with PDIA3 and CALR |
ERP27 ELISA Kit | publications with PDIA3 and ERP27 |
CANX ELISA Kit | publications with PDIA3 and CANX |
Pathways associated with PDIA3 ELISA Kit
Adaptive Immune System Pathway | Adaptive Immune System Pathway |
Antigen Presentation: Folding, Assembly And Peptide Loading Of Class I MHC Pathway | Antigen Presentation: Folding, Assembly And Peptide Loading Of Class I MHC Pathway |
Antigen Processing And Presentation Pathway | Antigen Processing And Presentation Pathway |
Antigen Processing-Cross Presentation Pathway | Antigen Processing-Cross Presentation Pathway |
Asparagine N-linked Glycosylation Pathway | Asparagine N-linked Glycosylation Pathway |
Calnexin/calreticulin Cycle Pathway | Calnexin/calreticulin Cycle Pathway |
Class I MHC Mediated Antigen Processing & Presentation Pathway | Class I MHC Mediated Antigen Processing & Presentation Pathway |
Defective ALG1 Causes ALG1-CDG (CDG-1k) Pathway | Defective ALG1 Causes ALG1-CDG (CDG-1k) Pathway |
Defective ALG11 Causes ALG11-CDG (CDG-1p) Pathway | Defective ALG11 Causes ALG11-CDG (CDG-1p) Pathway |
Diseases associated with PDIA3 ELISA Kit
Disease Models, Animal | publications with PDIA3 and Disease Models, Animal |
Inflammation | publications with PDIA3 and Inflammation |
Cardiovascular Diseases | publications with PDIA3 and Cardiovascular Diseases |
Nervous System Diseases | publications with PDIA3 and Nervous System Diseases |
Liver Diseases | publications with PDIA3 and Liver Diseases |
Brain Diseases | publications with PDIA3 and Brain Diseases |
Liver Neoplasms | publications with PDIA3 and Liver Neoplasms |
Immune System Diseases | publications with PDIA3 and Immune System Diseases |
Carcinoma, Hepatocellular | publications with PDIA3 and Carcinoma, Hepatocellular |
Fibrosis | publications with PDIA3 and Fibrosis |
Organs/Tissues associated with PDIA3 ELISA Kit
Blood | publications with PDIA3 and Blood |
Liver | publications with PDIA3 and Liver |
Bone | publications with PDIA3 and Bone |
Kidney | publications with PDIA3 and Kidney |
Brain | publications with PDIA3 and Brain |
Intestine | publications with PDIA3 and Intestine |
Muscle | publications with PDIA3 and Muscle |
Lung | publications with PDIA3 and Lung |
Vascular | publications with PDIA3 and Vascular |
Connective Tissue | publications with PDIA3 and Connective Tissue |